This article has been updated from a previous version, with clarifications and additional information about the personnel changes at Sequenom.
NEW YORK, July 22 (GenomeWeb News) - Jay Lichter, who was executive vice president of business development at Sequenom, has left the company, an outside company spokesperson confirmed today. Dereck Tatman, and Murlai Prahalad, who serve as directors of business development at Sequenom, have assumed the duties held by Lichter. Also Pete De Spain, manager of corporate communications at Sequenom, has left the company, and is now manager of corporate communications at Anadys Pharmaceuticals, of San Diego.
CytRx said July 20 that it has appointed Matthew Natalizio as the company's chief financial officer and announced today that it has Jack Barber as senior vice president of drug development.
Natalizo replaces Kirk Peacock. He comes to CytRx from Cisco Brothers, a private furniture company where he was most recently president and general manager. Before this, he was CFO at Qualstar. Natalizio has also served as a CPA and Ernst & Young, as well as a senior manager at KPMG.
Alamo Pharmaceuticals has appointed Paul Duffy executive vice president, the company said July 21. Duffy comes to the Beverly Hills, Calif., pharmaceutical CRO and marketing firm from Novartis, where he managed the marketing and sales of Clozaril (clozapine.) as the head of the neuroscience sales group.
Genomatica has named George Church, Leroy Hood, Eugene Myers, and Bernhard Palsson to its newly-formed scientific advisory board, the company said July 20. Palsson, co-founder of Genomatica and chairman of the SAB, is a professor of bioengineering and an adjunct Professor of medicine at the University of California, San Diego. Church is a professor of genetics at Harvard Medical School and director of the Lipper Center for Computational Genetics. Hood is co-founder and president of the Institute for Systems Biology, and is recognized as one of the world's leading scientists in molecular biotechnology and genomics. Myers is a professor of computer science at the University of California, Berkeley and formerly vice president of informatics research at Celera Genomics.
Leslie Browne has been appointed president and chief executive officer of Pharmacopeia Drug Discovery, the company said July 19. Browne has most recently been chief operating officer of Iconix Pharmaceuticals, which does chemogenomics, and chief operating officer of GeneTrace, a functional genomics company. Between 1990 to 2000 he held senior positions at Berlex/ Schering AG, and before that, held positions at Ciba Geigy. Browne received his PhD from the University of Michigan and was an NIH Postdoctoral Fellow at Harvard with Nobel laureate R.B. Woodward.
Alnylam Pharmaceuticals said July 19 that Thomas Ulich, the company's senior vice president of research and development, has resigned effective July 30 in order to "pursue other interests."
"We thank Tom for his important contributions to Alnylam's research effort over the past year and wish him the best," John Maraganore, CEO of Alnylam, said in a statement.
James Meer has been appointed vice president, chief financial officer, secretary, and treasurer of Pharmos, the company said July 19. Prior to joining Pharmos, Meer was a strategic consultant to specialty pharmaceutical and biotech firms. Meer served eight years as vice president and treasurer of Schein Pharmaceutical where he was responsible for capital formation, including a successful IPO, strategic planning and investor relations. He has also held positions at EnviroSource, John Labatt, and General Host Corporation.
Eric Fung has been promoted by Ciphergen to the position of vice president, clinical and medical affairs, in its new diagnostics division, the company said July 14. Fung will manage clinical and medical research underlying the company's clinical diagnostics business initiative in the area of protein molecular diagnostics.
Fung, who was most recently director of clinical affairs at Ciphergen, joined the company in 2000 as a lead scientist in its Biomarker Discovery Center laboratories, where he managed Ciphergen's Collaborations with academic and pharmaceutical companies. Before joining Ciphergen, he was a Howard Hughes sponsored researcher at Stanford University, in Richard Scheller's lab.